Pulmonary Arterial Hypertension
Conditions
Brief summary
Multicenter, double-blind, randomized, placebo-controlled, cross-over study to demonstrate that a single infusion of tezosentan has minimal effect on blood pressure in patients with pulmonary arterial hypertension, treated with endothelin receptor antagonists, phosphodiesterase-5 inhibitors or a combination of both.
Interventions
DRUGACT-050089
5 mg/h intravenously, Tezosentan
OTHERPlacebo
Matching placebo
Sponsors
Idorsia Pharmaceuticals Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
: 1. Signed informed consent prior to initiation of any study-mandated procedure 2. Male and female patients 18 years of age or older 3. Patients with PAH according to one of the following subgroups of the Dana Point Classification Group 1: * Idiopathic, or * Heritable, or * Associated with connective tissue disease 4. Documented hemodynamic diagnosis of PAH by right heart catheterization (not part of study mandated procedures): * Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and * Resting mean pulmonary vascular resistance (PVR) ≥ 240 dyn•s•cm 5 and * Pulmonary capillary wedge pressure ≤ 15 mmHg 5. Modified NYHA functional class II-III 6. Patients on treatment with ERAs, PDE-5 inhibitors or a combination of both, if used for at least 3 months prior to Visit 1 and dosing kept stable for at least 28 days prior to Visit 1.
Exclusion criteria
: 1. Patients with PAH in Dana Point Classification Groups 2-5, and PAH Group 1 subgroups not covered by inclusion criterion No. 3 2. Patients with sitting SBP \< 100 mmHg 3. Patients with sitting DBP \< 60 mmHg 4. Patients with body weight \< 50 kg (110 lbs) 5. Patients with clinically significantly elevated liver enzymes (AST, ALT and/or alkaline phosphatase \> 3 times upper limit) 6. Patients with clinically significant chronic renal insufficiency (serum creatinine \>2.5mg/dL / 221 µmol/L) 7. Patients with moderate or severe hepatic impairment (Child-Pugh B and C) 8. Patients who have received prostacyclin (epoprostenol) or prostacyclin analogs (e.g., treprostinil, iloprost and beraprost) within 28 days of Visit 1 9. Patients who have received any investigational drugs within 28 days of Visit 1 10. Patients who have received cyclosporine A (CsA) or tacrolimus within 28 days of Visit 1 11. Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with the study 12. Life expectancy less than 12 months 13. Females who are lactating or pregnant (positive pre-treatment pregnancy tests) (serum test at Screening and urine test on Visit 1 and 2) or females who are not using a reliable method of birth control (failure rate less than 1% per year) during the study and for at least one month after last administration of study drug 14. Known hypersensitivity to any of the excipients of the drug formulation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Absolute change in supine SBP from Baseline to 30 minutes at each visit (Visit 1 and Visit 2) - in mmHg | 30 days |
Secondary
| Measure | Time frame |
|---|---|
| Absolute change in heart rate from Baseline to 30 minutes at each visit (Visit 1 and Visit 2) - in bpm | 30 days |
Countries
France, Japan, United States
Outcome results
None listed